Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages

被引:234
作者
Bibby, MC [1 ]
机构
[1] Univ Bradford, Tom Connors Canc Res Ctr, Bradford BD7 1DP, W Yorkshire, England
关键词
orthotopic; experimental tumours; drug discovery;
D O I
10.1016/j.ejca.2003.11.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Considering the enormous effort that has taken place over the years to discover new chemotherapeutic drugs for treating the common cancers, the conventional murine and xenograft test systems used to test efficacy for drug development have identified only a limited number of useful agents that are active clinically at well tolerated doses. In recent years, considerable effort has been made to develop more clinically relevant models by the use of orthotopic transplantation of tumour material in rodents. It has been shown that it is now possible to transplant tumour material from a variety of tumour types into the appropriate anatomical site and often these tumours will metastasise in a similar manner and to similar locations as the same tumour type will in human cancer. As yet, although a body of literature has amassed on the technique itself and its implications for metastasis, there are relatively few laboratories using these test systems in drug development programmes. Nevertheless, given the expertise now being developed and some interesting observations being made on the role of the tumour site on response to therapeutic agents, it is likely that the use of orthotopic systems will strengthen our ability to select the most appropriate molecules for recommended use in clinical studies. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:852 / 857
页数:6
相关论文
共 49 条
[11]  
COWEN DM, 1980, J NATL CANCER I, V64, P675
[12]   CHARACTERIZATION OF THE VASCULATURE WITHIN A MURINE ADENOCARCINOMA GROWING IN DIFFERENT SITES TO EVALUATE THE POTENTIAL OF VASCULAR THERAPIES [J].
COWEN, SE ;
BIBBY, MC ;
DOUBLE, JA .
ACTA ONCOLOGICA, 1995, 34 (03) :357-360
[13]  
COWEN SE, 1994, BR J CANC S21, V69, P41
[14]   ENDOTHELIAL CELL-PROLIFERATION AS A NOVEL-APPROACH TO TARGETING TUMOR-THERAPY [J].
DENEKAMP, J .
BRITISH JOURNAL OF CANCER, 1982, 45 (01) :136-139
[15]   ORGAN-SPECIFIC MODULATION OF STEADY-STATE MDR GENE-EXPRESSION AND DRUG-RESISTANCE IN MURINE COLON-CANCER CELLS [J].
DONG, ZY ;
RADINSKY, R ;
FAN, D ;
TSAN, R ;
BUCANA, CD ;
WILMANNS, C ;
FIDLER, IJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (12) :913-920
[16]   THERAPEUTIC INDEX - A VITAL COMPONENT IN SELECTION OF ANTICANCER AGENTS FOR CLINICAL-TRIAL [J].
DOUBLE, JA ;
BIBBY, MC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (13) :988-994
[17]  
DOUBLE JA, 1978, CANCER TREAT REP, V62, P85
[18]  
DOUBLE JA, 1975, CANCER CHEMOTH REP 1, V59, P1083
[19]   Combined noninvasive imaging and luminometric quantification of luciferase-labeled human prostate tumors and metastases [J].
El Hilali, N ;
Rubio, N ;
Martinez-Villacampa, M ;
Blanco, J .
LABORATORY INVESTIGATION, 2002, 82 (11) :1563-1571
[20]   ORTHOTOPIC IMPLANTATION OF HUMAN COLON CARCINOMAS INTO NUDE-MICE PROVIDES A VALUABLE MODEL FOR THE BIOLOGY AND THERAPY OF METASTASIS [J].
FIDLER, IJ .
CANCER AND METASTASIS REVIEWS, 1991, 10 (03) :229-243